A5015633747- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Single-cell and spatial transcriptomics
- Genomic variations and chromosomal abnormalities
- CRISPR and Genetic Engineering
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Cytokine Signaling Pathways and Interactions
- Aquaculture Nutrition and Growth
- Gastrointestinal disorders and treatments
- Inflammasome and immune disorders
- Oral Health Pathology and Treatment
- Cancer Cells and Metastasis
- Gallbladder and Bile Duct Disorders
- Lung Cancer Research Studies
- Food and Agricultural Sciences
- Brain Metastases and Treatment
- MicroRNA in disease regulation
- Endometrial and Cervical Cancer Treatments
- Oral microbiology and periodontitis research
Sanford Burnham Prebys Medical Discovery Institute
2024
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2013-2024
Discovery Institute
2024
University of Southampton
2020
Moores Cancer Center
2019-2020
University of California, San Diego
2019-2020
Institute of Food Science
2014
Centro di Riferimento Oncologico
2013
Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information available on the predictive role of liquid patients treated with first-line anti-EGFR monoclonal antibody-based therapy.In CAPRI-GOIM trial, 340 KRAS exon-2 wild-type mCRC received cetuximab plus FOLFIRI. Tumor samples were retrospectively assessed by next generation sequencing (NGS). Baseline plasma analyzed and NRAS mutations using beads, emulsion, amplification,...
// Anna Maria Rachiglio 1 , Riziero Esposito Abate Alessandra Sacco Raffaella Pasquale Francesca Fenizia Matilde Lambiase Alessandro Morabito 2 Agnese Montanino Gaetano Rocco 3 Carmen Romano 4 Nappi Rosario Vincenzo Iaffaioli Fabiana Tatangelo 5 Gerardo Botti Fortunato Ciardiello 6 Monica R. Maiello 7 Antonella De Luca Nicola Normanno 1, Laboratory of Pharmacogenomics, CROM-Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy Thoraco-Pulmonary, Medical Oncology, Istituto...
The activity of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab in metastatic colorectal carcinoma (mCRC) is significantly limited by molecular mechanisms leading to intrinsic or acquired resistance. S492R mutation EGFR, which caused either 1476C>A 1474A>C substitution, interferes with binding but not panitumumab, has been detected mCRC resistance cetuximab. Since EGFR monoclonal CRC overlap, we evaluated frequency a series KRAS-exon 2 wild-type patients....
Aim: We assessed the ability of Therascreen® kit (plasma-Therascreen) and a peptide nucleic acids (PNA)-clamp approach to detect EGFR mutations in plasma-derived circulating-free tumor DNA (cftDNA) from non-small-cell lung cancer patients. Materials & methods: cftDNA 96 patients was analyzed for exon 19 deletions p.L858R mutation, using both plasma-Therascreen PNA-clamp-based assays. Results: None 70 wild-type showed with techniques (specificity: 100%). In 17/26 EGFR-mutant patients,...
The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the efficacy, safety, and tolerability of rechallenge treatment with first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-small-cell lung cancer (NSCLC) patients carrying activating mutations epidermal growth factor receptor (EGFR). enrolled 61 who were rechallenged at progression after second-line chemotherapy. Serum-derived circulating cell-free DNA (cfDNA) collected...
Abstract Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods TMB testing have not yet standardized. The International Quality Network Pathology (IQNPath) organized a pilot external quality assessment (EQA) scheme testing. aim of this program was the validation materials and procedures EQA complex biomarker. Five formalin-fixed paraffin-embedded (FFPE) cell lines were selected to mimic various values observed in...
Targeted sequencing of circulating cell-free DNA (cfDNA) is used in routine clinical diagnostics for the identification predictive biomarkers cancer patients an advanced stage. The presence KRAS mutations associated with clonal hematopoiesis indeterminate potential (CHIP) might represent a confounding factor. We amplicon-based targeted panel, covering selected regions 52 genes, total nucleic acid (cfTNA) analysis 495 plasma samples from patients. cfDNA test failed 4 cases, while RNA (cfRNA)...
3046 Background: In mCRC patients RAS/BRAF testing is usually performed on tissue biopsy in order to select for treatment with anti-EGFR monoclonal antibodies. Several studies described discordant RAS status between and cfDNA from the same patients. addition, up 30% of secondary resistance therapies become mutant at progression. The LIBImAb study a phase III, randomized, open-label, comparative, multi-centre trial assess superiority terms efficacy bevacizumab versus cetuximab combination...
Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive course, characterized by limited number metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define oligometastatic behavior remain uncertain. In this study, we present protocol designed prospectively identify OMD, with aim proposing novel therapeutic approaches...
Although conflicting results emerged from different studies, the tumor mutational burden (TMB) appears as one of most reliable biomarkers sensitivity to immune checkpoint inhibitors. Several laboratories are reporting TMB values when performing comprehensive genomic profiling (CGP) without providing a clinical interpretation, due lack validated cut-off values. The International Quality Network for Pathology launched an initiative harmonize testing with CGP assay and favor implementation this...
Abstract Age is a major risk factor for liver cancer, as the case most adult human cancers. However, underlying mechanisms are not well defined. A better understanding of role aging in and other cancers can facilitate approaches assessment, early detection prevention. We hypothesize that age-driven changes render aged more sensitive to oncogenic stress hence tumorigenesis. To investigate how with age, we documented immune profile, transcriptome epigenome healthy livers from both young mice,...
<title>Abstract</title> Age is a major risk factor for liver cancer, as the case most adult human cancers. However, underlying mechanisms are not well defined. A better understanding of role aging in and other cancers can facilitate approaches assessment, early detection prevention. We hypothesize that age-driven changes render aged more sensitive to oncogenic stress hence tumorigenesis. To investigate how with age, we documented immune profile, transcriptome epigenome healthy livers from...